Abdominal Distension News and Research

RSS

Gut health and leukemia: Exploring the crucial connection between diet and microbiota changes

Gut microbiota's role in leukemia treatment responses is explored, with evidence suggesting diet and prebiotics may help manage microbiota alterations in patients. Diet during pregnancy, breastfeeding, and gut microbiota composition all intersect, potentially influencing leukemia risks and treatment outcomes.

8 Oct 2023

Assessing the efficacy, safety and tolerability of AXA1125 in long COVID patients

Researchers evaluated the effectiveness of endogenous metabolic modulator, AXA1125.

19 Apr 2023

The burden of Clostridioides difficile infections in the United States

Researchers review existing data on Clostridioides difficile infections among United States residents.

13 Mar 2023

Study investigates intestinal ischemia in COVID-19 patients

A team of Italian scientists has presented case reports of five coronavirus disease 2019 (COVID-19) patients undergoing emergency surgery for intestinal ischemia.

28 Apr 2022

Gas-related symptoms linked to depression, anxiety, stress and poorer quality of life

Gas-related symptoms are associated with poorer quality of life, and higher stress, anxiety, and depression, with breaking wind being the most frequently reported gas issue, affecting eight out of 10 adults in the general population (81.3 %) in a 24-hour period, according to a new survey1 being presented today at UEG Week Virtual 2021.

4 Oct 2021

Weight loss drug Wegovy approved by FDA

The U.S. Food and Drug Administration (FDA) has approved Wegovy (semaglutide) injection (2.4 mg once weekly) as a chronic weight management treatment in obese or overweight adults with a weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol), when used along with calorie restriction and physical activity. Wegovy, is a more potent version of Novo Nordisk's diabetes drug semaglutide.

4 Jun 2021

Pandemic-fueled alcohol abuse creates wave of hospitalizations for liver disease

As the pandemic sends thousands of recovering alcoholics into relapse, hospitals across the country have reported dramatic increases in alcohol-related admissions for critical diseases like alcoholic hepatitis and liver failure.

10 Feb 2021

No added risks to radiation therapy for cancer patients with COVID-19, says study

A team of radiation oncologists at the Zucker School of Medicine at Hofstra/Northwell in the United States aimed to determine if COVID-19 infected cancer patients receiving radiation therapy (RT) have any different outcome than non-infected patients.

17 Dec 2020

Study shows global prevalence of functional gastrointestinal disorders

For every ten adults in the world, four suffer from functional gastrointestinal disorders of varying severity. This is shown by a study of more than 73,000 people in 33 countries. University of Gothenburg scientists are among those now presenting these results.

27 May 2020

Identifying foods that trigger IBS: an interview with Dr Bill Chey

IBS is a common medical condition which is diagnosed in the presence of characteristic gastrointestinal symptoms including recurring bouts of abdominal pain and diarrhea and/or constipation. IBS patients also commonly report bloating and abdominal distension or swelling.

15 Nov 2016

Simple method to determine prevalence of celiac disease in children aged 2-4

Researchers from the University of Granada have developed a new, simple and non invasive method which allows to determine whether a child aged 2-4 suffers from celiac disease or not without the necessity of a blood extraction.

11 Mar 2016

Vernalis Therapeutics announces availability of codeine-based cough and cold syrup in the U.S.

Vernalis Therapeutics Inc., a subsidiary of Vernalis plc, today announced that Tuzistra XR (codeine polistirex and chlorpheniramine polistirex), extended-release oral suspension, CIII (DEA Schedule III) is now available to adult patients and physicians in the United States.

8 Sep 2015

Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

Results from a new study of Japanese patients with type 2 diabetes showed once-weekly Trulicity 0.75 mg provided greater hemoglobin A1c (A1C) reduction compared to once-daily Victoza 0.9 mg after 52 weeks of treatment. Eli Lilly and Company will present these data at the 75th American Diabetes Association Scientific Sessions in Boston.

7 Jun 2015

Bayer HealthCare receives FDA approval for Adempas tablets

Bayer HealthCare announced today that the United States Food and Drug Administration has approved Adempas (riociguat) tablets for: (i) the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class; and (ii) the treatment of adults with pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity, improve WHO functional class and delay clinical worsening.

9 Oct 2013

European authorisation of Aegerion Pharmaceuticals' Lojuxta brings hope for HoFH patients

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialisation of novel, life-altering therapies for patients with debilitating, often fatal, rare diseases, announced today that the European Commission has authorised Lojuxta (lomitapide) hard capsules as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein apheresis in adult patients with homozygous familial hypercholesterolaemia.

3 Aug 2013

Juice products from Juices Incorporated have potential health risk, FDA warns

The U.S. Food and Drug Administration is warning consumers not to consume any juice products or other beverages from Juices Incorporated (aka Juices International and Juices Enterprises) of Brooklyn, N.Y.

13 May 2013

Data from Alvine’s ALV003 Phase 2A trial on celiac disease presented at DDW 2012

Alvine Pharmaceuticals, Inc. today announced the presentation of data from a Phase 2A trial of its lead compound, ALV003, at the 2012 Digestive Diseases Week (DDW) meeting held in San Diego, California. The study results met the primary endpoint of demonstrating that oral ALV003, administered in the context of a gluten free diet (GFD), can diminish gluten-induced intestinal mucosal injury in well-controlled celiac disease patients. The company plans to initiate a Phase 2B trial later this year.

23 May 2012

Hypnotherapy effective for treating bowel disorder IBS

Hypnosis can be a highly effective treatment for the bowel disorder IBS. Studies involving a total of 346 patients conducted by researchers at The Sahlgrenska Academy of the University of Gothenburg, Sweden, showed that hypnotherapy alleviated symptoms in 40 per cent of those affected - and that the improvement is long-term.

2 Apr 2012

Rifaximin and lubiprostone offer best options for patients with IBS

Cedars-Sinai researchers have determined that two prevalent drug therapies - rifaximin and lubiprostone - offer some of the best options for treating irritable bowel syndrome, a widespread disorder that affects up to one in five Americans.

26 Mar 2012

New algorithm could help GPs identify women at risk of early ovarian cancer

The lives of hundreds of women could be saved every year, thanks to a simple online calculator that could help GPs identify women most at risk of having ovarian cancer at a much earlier stage.

5 Jan 2012